S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Laser breakthrough could send stock soaring 2,467% (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

$5.11
-0.15 (-2.85%)
(As of 02/22/2024 ET)
Today's Range
$5.05
$5.24
50-Day Range
$5.11
$6.87
52-Week Range
$4.52
$16.90
Volume
2.81 million shs
Average Volume
2.07 million shs
Market Capitalization
$1.28 billion
P/E Ratio
28.39
Dividend Yield
N/A
Price Target
$13.22

Maravai LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
132.4% Upside
$11.88 Price Target
Short Interest
Bearish
6.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.52mentions of Maravai LifeSciences in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.10) to ($0.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.33 out of 5 stars

Medical Sector

119th out of 934 stocks

Pharmaceutical Preparations Industry

46th out of 421 stocks


MRVI stock logo

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Stock Price History

MRVI Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Maravai LifeSciences (MRVI) to Release Earnings on Thursday
MRVI Jan 2025 5.000 call
MRVI Jan 2025 10.000 put
MRVI Sep 2024 5.000 call
MRVI Jun 2024 15.000 call
Maravai LifeSciences Holdings Inc.
Maravai Lifesciences Holdings Inc (MRVI)
Maravai LifeSciences: Still Trying To Right The Ship
Maravai LifeSciences Holdings
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2023
Today
2/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
670
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.88
High Stock Price Target
$18.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+158.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$220.21 million
Pretax Margin
13.69%

Debt

Sales & Book Value

Annual Sales
$883 million
Cash Flow
$1.89 per share
Book Value
$3.55 per share

Miscellaneous

Free Float
250,730,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
-0.19
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Carl W. Hull (Age 65)
    Co-Founder & Executive Chairman
    Comp: $1.45M
  • Mr. William E. Martin III (Age 49)
    Chief Executive Officer
    Comp: $2.07M
  • Mr. Kevin M. Herde (Age 52)
    Executive VP & CFO
    Comp: $778.28k
  • Dr. Peter Michael Leddy Ph.D. (Age 61)
    Executive VP & Chief Administrative Officer
    Comp: $757k
  • Ms. Christine Dolan (Age 56)
    Executive Vice President of Biologics Safety Testing
    Comp: $755.97k
  • Ms. Debra Hart
    Senior Director of Investor Relations
  • Mr. Kurt Oreshack (Age 43)
    Executive VP, General Counsel & Secretary
    Comp: $701.4k
  • Ms. Becky Buzzeo
    Executive VP & Chief Commercial Officer
  • Dr. Kate E. Broderick Ph.D.
    Chief Innovation Officer
  • Mr. Christopher Benoit
    Executive Vice President of Enzymes














MRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRVI shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price target for 2024?

8 brokerages have issued 1 year price targets for Maravai LifeSciences' stock. Their MRVI share price targets range from $7.00 to $18.00. On average, they predict the company's share price to reach $11.88 in the next twelve months. This suggests a possible upside of 132.4% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2024?

Maravai LifeSciences' stock was trading at $6.55 at the beginning of the year. Since then, MRVI shares have decreased by 22.0% and is now trading at $5.11.
View the best growth stocks for 2024 here
.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its earnings results on Monday, May, 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.01. The company had revenue of $79.03 million for the quarter, compared to analysts' expectations of $79.72 million. Maravai LifeSciences had a trailing twelve-month return on equity of 9.38% and a net margin of 5.86%. The business's revenue for the quarter was down 67.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.54 earnings per share.

What ETFs hold Maravai LifeSciences' stock?
What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $261.0 million.

When did Maravai LifeSciences IPO?

(MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.98%), Massachusetts Financial Services Co. MA (2.39%), Mackenzie Financial Corp (2.06%), Braidwell LP (2.01%), Pacer Advisors Inc. (1.18%) and Point72 Europe London LLP (1.04%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRVI) was last updated on 2/23/2024 by MarketBeat.com Staff